This Code of Conduct is the first step to showing dedication to upholding continuous excellence in both business and ethical terms, and showing our care and dedication to products, clients and success.
Code of conduct
- Published:
- written by: Polpharma Biologics
Related news
Other news related to this topic that may be of interest to you
Polpharma Biologics and PSI CRO Collaborate on Phase 1 Biosimilar Study in Multiple Sclerosis
June 03, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development...
Polpharma Biologics and Tuteur sign a licensing agreement for a biosimilar targeting autoimmune diseases
May 22, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development...
Bioeq and Zydus partners for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA
December 23, 2025 –Polpharma Biologics is pleased to acknowledge the recent announcement of Bioeq AG,...
Polpharma Biologics and Libbs Farmacêutica sign licensing agreement for a biosimilar for autoimmune diseases
December 10, 2025 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development...